Why does the leukemia type change immunotherapy options? A U.S. blinatumomab consolidation indication for B-cell acute lymphoblastic leukemia (B-ALL) is not an indication for acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Even within B-ALL, the CD19 result, Philadelphia chromosome status and chemotherapy phase change whether that indication applies.[1] Prior drugs change the CLL/SLL CAR T discussion; the cited chronic myeloid leukemia (CML) drug is a kinase inhibitor, not an immunotherapy.
Review status: This article has not been individually reviewed by a physician.

B-ALL: Marker and treatment stage
If B-ALL is CD19-positive and Philadelphia chromosome-negative, blinatumomab has a U.S. consolidation indication from age one month onward within multiphase chemotherapy.[1]
The FDA-reviewed E1910 trial randomized 112 adults per arm with newly diagnosed Philadelphia chromosome-negative B-ALL after induction and intensification chemotherapy, when they had reached complete remission or remission with incomplete blood-count recovery. Three-year Kaplan–Meier overall-survival estimates were 84.8% with blinatumomab-containing consolidation and 69.0% with chemotherapy-only consolidation. Those estimates describe adults in E1910, not children or people with AML, CLL/SLL or CML; the trial did not test dropping chemotherapy.[1]
For B-cell precursor ALL that has not responded or has relapsed, CAR T eligibility differs by product. U.S. tisagenlecleucel is for people up to age 25 with refractory disease or a second or later relapse.[2] U.S. obecabtagene autoleucel is for adults with relapsed or refractory disease.[3] Unlike the cited blinatumomab consolidation indication, neither of these two CAR T approvals states a Philadelphia chromosome-negative requirement.[1][2][3]
AML: CD33 and transplant risk
Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate, not CD19 CAR T. Its U.S. indications cover newly diagnosed CD33-positive AML in adults and children aged one month or older, and relapsed or refractory CD33-positive AML in adults and children aged two years or older.[4][5]
In ALFA-0701, hepatic veno-occlusive disease occurred in 6 of 131 adults (5%) treated with gemtuzumab plus daunorubicin/cytarabine during or after treatment or after a later stem-cell transplant. The trial enrolled adults aged 50–70; three of the 6 events were fatal. This is a treated-arm count, not a personal risk estimate. If a transplant is planned, ask your specialist about gemtuzumab’s liver risks and transplant timing.[4]
CLL/SLL: Which treatments came first?
In the U.S., lisocabtagene maraleucel CAR T has accelerated approval for adults with relapsed or refractory CLL/SLL after at least two prior treatment lines, including a BTK inhibitor and a BCL-2 inhibitor.[6] The FDA based this approval on response rate and duration of response. TRANSCEND CLL 004 was single-arm, so it cannot show whether this treatment extends life more than a targeted drug.[7]
CML: A different drug class
Asciminib is a kinase inhibitor, not an immunotherapy. On October 29, 2024, the FDA granted it accelerated approval for adults with newly diagnosed Philadelphia chromosome-positive CML in chronic phase.[8]
What to check with a specialist
For a specialist appointment, gather the pathology report with the leukemia subtype and any CD19, CD33 or Philadelphia chromosome results, plus your current disease status and a dated treatment list. For CLL/SLL, note whether you have received a BTK inhibitor and a BCL-2 inhibitor; for AML, flag any planned stem-cell transplant. These records help a clinician check product-specific rules, but do not establish eligibility on their own. If you need help organizing records or requesting an appointment, this site’s explanation of its coordination role describes practical assistance, not clinical decision-making.
The FDA labels for blinatumomab and lisocabtagene maraleucel warn of cytokine release syndrome and neurologic toxicity.[1][9] These U.S. approvals do not establish Japanese approval, insurance coverage, local access, or a treatment offered by this website. Ask your treating center to check what is actually available where you live.
Ask about records or appointments
Sources
- [1] FDA. Blincyto U.S. prescribing information, E1910 and consolidation indication. Revised December 2024; indication approved June 14, 2024.
- [2] FDA. Kymriah original approval letter. August 30, 2017.
- [3] FDA. Aucatzyl original approval letter. November 8, 2024.
- [4] FDA. Mylotarg prescribing information, ALFA-0701 safety. September 2017.
- [5] FDA. Pediatric newly diagnosed CD33-positive AML indication extension. June 16, 2020.
- [6] FDA. Breyanzi accelerated-approval letter for CLL/SLL. Effective March 14, corrected March 21, 2024.
- [7] Siddiqi T, et al. TRANSCEND CLL 004, single-arm phase 1–2 study. Lancet. 2023;402:641–654.
- [8] FDA. Scemblix accelerated-approval letter. October 29, 2024.
- [9] FDA. Breyanzi U.S. prescribing information and boxed warnings. Consult the current label.